Monkeypox Virus Infections After 2 Preexposure Doses of JYNNEOS Vaccine — United States, May 2022–May 2024

  • Guagliardo S
  • Kracalik I
  • Carter R
  • et al.
16Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.

Abstract

Two doses of JYNNEOS vaccine are effective in preventing many mpox cases and can reduce the severity of symptoms in infected persons. However, infections among fully vaccinated persons can occur. During May 2022-May 2024, a total of 271 mpox cases among fully vaccinated persons were reported to CDC from 27 U.S. jurisdictions. These reported infections are estimated to have occurred in <1% of fully vaccinated persons. Compared with cases among unvaccinated persons, infections among fully vaccinated persons were more likely to occur among non-Hispanic White men aged 30-39 years, were associated with increased numbers of sexual partners, and resulted in less severe disease (p<0.001). Among infections in fully vaccinated persons with complete data, infections after vaccination were reported more commonly after receipt of heterologous (subcutaneous and intradermal) (46%) or homologous subcutaneous (32%) JYNNEOS vaccination than after homologous intradermal (22%) vaccination. Disparate time intervals from vaccination to infection among fully vaccinated persons suggest that immunity is not waning. The median interval between the second vaccine dose and illness onset was longer for cases among persons who had received 2 intradermal doses (median = 363 days; IQR = 221-444 days) compared with cases in persons who had received 2 subcutaneous doses (median = 263 days; IQR = 47-334 days) (p<0.001). The implications of this finding are not known; however, these data should increase confidence in the effectiveness of vaccine doses that were administered intradermally, the preferred method of administration during the peak of the outbreak when vaccine supply was limited. Persons recommended to receive the JYNNEOS vaccine should receive 2 doses, irrespective of the route of administration, and at this time, additional doses are not recommended for the affected population.

References Powered by Scopus

Monkeypox Outbreak - Nine States, May 2022

241Citations
N/AReaders
Get full text

Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United States

146Citations
N/AReaders
Get full text

Severe Monkeypox in Hospitalized Patients - United States, August 10-October 10, 2022

142Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Vaccines against mpox: MVA-BN and LC16m8

13Citations
N/AReaders
Get full text

Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis

10Citations
N/AReaders
Get full text

Effectiveness and Safety of the MVA–BN Vaccine against Mpox in At-Risk Individuals in the United States (USMVAc)

5Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Guagliardo, S. A. J., Kracalik, I., Carter, R. J., Braden, C., Free, R., Hamal, M., … Rao, A. K. (2024). Monkeypox Virus Infections After 2 Preexposure Doses of JYNNEOS Vaccine — United States, May 2022–May 2024. MMWR. Morbidity and Mortality Weekly Report, 73(20), 460–466. https://doi.org/10.15585/mmwr.mm7320a3

Readers over time

‘24‘2505101520

Readers' Seniority

Tooltip

Researcher 11

69%

PhD / Post grad / Masters / Doc 5

31%

Readers' Discipline

Tooltip

Medicine and Dentistry 7

44%

Nursing and Health Professions 3

19%

Immunology and Microbiology 3

19%

Social Sciences 3

19%

Article Metrics

Tooltip
Mentions
News Mentions: 9
Social Media
Shares, Likes & Comments: 19

Save time finding and organizing research with Mendeley

Sign up for free
0